Kawashima Ichiro, Sueki Yuki, Yamamoto Takeo, Nozaki Yumi, Nakajima Kei, Mitsumori Toru, Kirito Keita
Department of Hematology/Oncology, University of Yamanashi.
Rinsho Ketsueki. 2015 Feb;56(2):210-5. doi: 10.11406/rinketsu.56.210.
Adult T cell lymphoma-leukemia (ATL) is a highly aggressive disease and allogeneic hematopoietic transplantation (allo-HSCT) is the only therapeutic option for achieving a cure. However, some ATL patients cannot undergo HSCT. One of the important reasons for restricting HSCT in ATL is the high incidence of pulmonary complications associated with ATL including opportunistic infections, infiltration of ATL cells, and HTLV-1 associated bronchopneumonopathy. Herein, we report an ATL case with pulmonary infiltration of ATL cells successfully treated with allo-HSCT after improvement of pulmonary function with administration of the anti-CCR4 antibody mogamulizumab. To our knowledge, this is the first ATL case showing improvement of pulmonary invasion of ATL cells after treatment with mogamulizumab. In addition, this case suggests that mogamulizumab treatment might be useful as a bridge to allo-HSCT in ATL patients.
成人T细胞淋巴瘤白血病(ATL)是一种侵袭性很强的疾病,异基因造血移植(allo-HSCT)是实现治愈的唯一治疗选择。然而,一些ATL患者无法进行HSCT。限制ATL患者进行HSCT的一个重要原因是与ATL相关的肺部并发症发生率很高,包括机会性感染、ATL细胞浸润以及HTLV-1相关支气管肺炎。在此,我们报告1例ATL细胞肺部浸润的ATL病例,在使用抗CCR4抗体莫加莫拉单抗改善肺功能后成功接受allo-HSCT治疗。据我们所知,这是首例经莫加莫拉单抗治疗后ATL细胞肺部浸润得到改善的ATL病例。此外,该病例提示莫加莫拉单抗治疗可能作为ATL患者allo-HSCT的桥梁是有用的。